O	0	5	Phase
O	6	8	II
O	9	19	randomized
O	20	28	clinical
O	29	34	trial
O	35	45	evaluating
O	46	57	neoadjuvant
O	58	70	chemotherapy
O	71	79	regimens
O	80	84	with
B-intervention	85	91	weekly
I-intervention	92	102	paclitaxel
O	103	105	or
B-control	106	114	eribulin
I-control	115	123	followed
I-control	124	126	by
I-control	127	138	doxorubicin
I-control	139	142	and
I-control	143	159	cyclophosphamide
O	160	162	in
O	163	168	women
O	169	173	with
O	174	181	locally
O	182	190	advanced
O	191	195	HER2
O	195	196	-
O	196	204	negative
O	205	211	breast
O	212	218	cancer
O	218	219	:
O	220	225	NSABP
O	226	236	Foundation
O	237	242	Study
O	243	245	FB
O	245	246	-
O	246	247	9
O	247	248	.

O	249	256	Locally
O	257	265	advanced
O	266	272	breast
O	273	279	cancer
O	280	281	(
O	281	285	LABC
O	285	286	)
O	287	289	is
O	290	291	a
O	292	296	good
O	297	304	setting
O	305	307	in
O	308	313	which
O	314	316	to
O	317	324	monitor
O	325	333	response
O	334	336	to
O	337	348	neoadjuvant
O	349	361	chemotherapy
O	361	362	,
O	363	365	to
O	366	374	downsize
O	375	378	the
O	379	384	tumor
O	385	386	(
O	386	391	which
O	392	403	facilitates
O	404	410	breast
O	410	411	-
O	411	421	conserving
O	422	429	surgery
O	429	430	)
O	430	431	,
O	432	435	and
O	436	438	to
O	439	443	test
O	444	449	newer
O	450	456	agents
O	457	459	in
O	460	469	untreated
O	470	478	patients
O	478	479	.

O	480	488	Eribulin
O	489	490	(
O	490	491	E
O	491	492	)
O	493	496	has
O	497	502	shown
O	503	511	activity
O	512	514	in
O	515	523	patients
O	524	527	who
O	528	532	have
O	533	542	undergone
O	543	551	previous
O	552	558	taxane
O	558	559	,
O	560	573	anthracycline
O	573	574	,
O	575	578	and
O	579	591	capecitabine
O	592	601	treatment
O	601	602	.

O	603	605	We
O	606	611	aimed
O	612	614	to
O	615	623	evaluate
O	624	627	the
O	628	639	neoadjuvant
O	640	643	use
O	644	646	of
O	647	648	E
O	649	657	followed
O	658	660	by
O	661	672	doxorubicin
O	673	676	and
O	677	693	cyclophosphamide
O	694	695	(
O	695	697	AC
O	697	698	)
O	699	701	in
O	702	710	patients
O	711	715	with
O	716	720	HER2
O	720	721	-
O	721	729	negative
O	730	734	LABC
O	734	735	,
O	736	741	using
O	742	744	as
O	745	746	a
O	747	754	control
O	755	756	a
O	757	767	randomized
O	768	773	group
O	774	776	of
O	777	782	women
O	783	786	who
O	787	795	received
O	796	802	weekly
O	803	813	paclitaxel
O	814	815	(
O	815	817	WP
O	817	818	)
O	818	819	.

B-total-participants	820	825	Fifty
B-eligibility	826	831	women
I-eligibility	832	836	with
I-eligibility	837	841	LABC
O	842	846	were
O	847	854	accrued
O	855	862	January
O	862	863	-
O	863	869	August
O	870	874	2013
O	874	875	.

O	876	884	Patients
O	885	889	were
O	890	900	randomized
O	901	902	(
O	902	903	1
O	903	904	:
O	904	905	2
O	905	906	)
O	907	909	to
O	910	917	receive
O	918	924	either
O	925	927	WP
O	928	929	(
O	929	930	N
O	931	932	=
B-intervention-participants	933	935	19
O	935	936	)
O	937	940	for
O	941	943	12
O	944	954	treatments
O	955	957	or
O	958	959	E
O	960	961	(
O	961	962	N
O	963	964	=
B-control-participants	965	967	31
O	967	968	)
O	969	974	every
O	975	976	3
O	977	982	weeks
O	983	986	for
O	987	988	4
O	989	995	cycles
O	996	1004	followed
O	1005	1007	by
O	1008	1010	AC
O	1011	1016	every
O	1017	1018	3
O	1019	1024	weeks
O	1025	1028	for
O	1029	1030	4
O	1031	1037	cycles
O	1038	1044	before
O	1045	1052	surgery
O	1052	1053	.

B-intervention-participants	1054	1056	17
O	1056	1057	/
O	1057	1059	19
O	1060	1068	patients
O	1069	1072	who
O	1073	1077	took
O	1078	1080	WP
O	1081	1084	and
B-control-participants	1085	1087	25
O	1087	1088	/
O	1088	1090	30
O	1091	1094	who
O	1095	1099	took
O	1100	1101	E
O	1102	1111	completed
O	1112	1115	all
O	1116	1122	cycles
O	1122	1123	.

O	1124	1132	Patients
O	1133	1137	were
O	1138	1147	evaluated
O	1148	1150	by
O	1151	1159	clinical
O	1160	1171	examination
O	1172	1175	and
O	1176	1182	breast
O	1183	1186	MRI
O	1187	1189	at
O	1190	1198	baseline
O	1199	1202	and
O	1203	1208	after
O	1209	1219	completion
O	1220	1222	of
O	1223	1224	E
O	1225	1227	or
O	1228	1230	WP
O	1230	1231	.

O	1232	1240	Surgical
O	1241	1244	pCR
O	1245	1247	in
O	1248	1254	breast
O	1255	1258	and
O	1259	1264	lymph
O	1265	1270	nodes
O	1271	1274	was
O	1275	1285	determined
O	1286	1288	by
O	1289	1290	a
O	1291	1296	local
O	1297	1308	pathologist
O	1309	1318	following
O	1319	1331	chemotherapy
O	1331	1332	.

O	1333	1338	Forty
O	1338	1339	-
O	1339	1343	nine
O	1344	1352	patients
O	1353	1361	received
O	1362	1363	â‰¥
O	1363	1364	1
O	1365	1369	dose
O	1370	1372	of
O	1373	1384	neoadjuvant
O	1385	1397	chemotherapy
O	1398	1401	and
O	1402	1405	are
O	1406	1414	included
O	1415	1417	in
O	1418	1422	this
O	1423	1431	analysis
O	1431	1432	.

O	1433	1438	Forty
O	1438	1439	-
O	1439	1444	eight
O	1445	1454	underwent
O	1455	1462	surgery
O	1462	1463	;
O	1464	1467	one
O	1468	1471	had
O	1472	1479	disease
O	1480	1484	that
O	1485	1488	was
O	1489	1499	inoperable
O	1500	1501	(
O	1501	1503	on
O	1504	1505	E
O	1505	1506	)
O	1507	1510	and
O	1511	1513	is
O	1514	1522	included
O	1523	1525	as
O	1526	1528	no
O	1528	1529	-
O	1529	1532	pCR
O	1533	1540	patient
O	1540	1541	.

B-iv-bin-abs	1542	1544	17
O	1544	1545	/
B-intervention-participants	1545	1547	19
O	1548	1550	of
O	1551	1556	these
O	1557	1565	patients
O	1566	1569	who
O	1570	1574	took
O	1575	1577	WP
B-outcome	1578	1587	completed
O	1588	1590	12
O	1591	1596	doses
O	1596	1597	;
B-cv-bin-abs	1598	1600	28
O	1600	1601	/
B-control-participants	1601	1603	30
O	1604	1606	on
O	1607	1608	E
O	1609	1618	completed
O	1619	1620	4
O	1621	1627	cycles
O	1627	1628	.

O	1629	1632	Six
B-outcome	1633	1645	discontinued
I-outcome	1646	1655	treatment
O	1656	1658	on
O	1659	1661	WP
O	1661	1662	,
O	1663	1664	E
O	1664	1665	,
O	1666	1668	or
O	1669	1671	AC
O	1671	1672	.

O	1673	1677	Both
O	1678	1688	treatments
O	1689	1693	were
B-outcome	1694	1698	well
I-outcome	1699	1708	tolerated
O	1708	1709	.

B-outcome	1710	1713	pCR
O	1714	1716	on
O	1717	1719	WP
O	1720	1721	=
B-iv-bin-abs	1722	1723	5
O	1723	1724	/
B-intervention-participants	1724	1726	19
O	1726	1727	(
B-iv-bin-percent	1727	1729	26
I-iv-bin-percent	1729	1730	%
O	1730	1731	)
O	1732	1735	and
O	1736	1738	on
O	1739	1740	E
O	1741	1742	=
B-cv-bin-abs	1743	1744	5
O	1744	1745	/
B-control-participants	1745	1747	30
O	1747	1748	(
B-cv-bin-percent	1748	1750	17
I-cv-bin-percent	1750	1751	%
O	1751	1752	)
O	1752	1753	.

O	1754	1758	Both
O	1759	1767	regimens
O	1768	1772	were
O	1773	1780	equally
B-outcome	1781	1785	well
I-outcome	1786	1795	tolerated
O	1796	1800	with
O	1801	1803	no
O	1804	1814	unexpected
O	1815	1825	toxicities
O	1825	1826	.

O	1827	1830	pCR
O	1831	1834	did
O	1835	1838	not
O	1839	1846	suggest
O	1847	1853	higher
O	1854	1862	activity
O	1863	1867	with
O	1868	1869	E
O	1870	1874	than
O	1875	1879	with
O	1880	1885	other
O	1886	1894	standard
O	1895	1903	regimens
O	1904	1906	in
O	1907	1912	these
O	1913	1917	LABC
O	1918	1926	patients
O	1926	1927	.
